A.G. v. United States - Civil Case Filing

A new civil case, A.G. v. United States of America (Federal Bureau of Prisons) et al, was filed on March 11, 2026, in the U.S. District Court for the Northern District of California. The case number is 3:26-cv-02139. The initial filings include a complaint, proposed summons, a motion to maintain plaintiff anonymity, and a consent to proceed before a US Magistrate Judge.

Ji v. Bondi et al - Civil Case Filing

A new civil case, Ji v. Bondi et al, was filed on March 11, 2026, in the U.S. District Court for the Northern District of California. The case involves the U.S. Government as a defendant and is based on the Administrative Procedures Act. The filing fee was $405.

CMA examines heating oil prices amid Middle East conflict

The UK's Competition and Markets Authority (CMA) is examining concerns about rising heating oil prices due to the Middle East conflict. The CMA is investigating reports of cancelled orders and significant price increases, engaging with suppliers to assess potential breaches of consumer protection law.

DOJ Audit of OJP IoT and Opioid Grants to Oklahoma State University

The Department of Justice's Office of the Inspector General has released an audit report (26-033) concerning the Office of Justice Programs' Internet of Things National Training and Technical Assistance Program and Opioid Affected Youth Initiative grants awarded to Oklahoma State University. The audit identified $292,977 in questioned costs and made five recommendations.

FDA Warning Letter to Tentamus India Private Limited

The FDA issued a warning letter to Tentamus India Private Limited for significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The violations include the quality control unit failing to ensure CGMP compliance and the destruction or improper handling of analytical records.

FDA Warning Letter to SSS AUSTAR LLC for Tobacco Products

The FDA issued a warning letter to SSS AUSTAR LLC for illegally marketing nicotine pouch products without required premarket authorization. The company's product, ZIMO MINT 6MG, is considered adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act.

FDA Warning Letter to Nu Skin Enterprises for Drug Listing Violations

The FDA issued a warning letter to Nu Skin Enterprises for violations related to drug listing obligations under the Federal Food, Drug, and Cosmetic Act. The company failed to update manufacturing establishment information and has 61 inactivated drug listings. The FDA requires corrective action within 15 working days.

FDA Warning Letter to snushaven.com for Nicotine Pouches

The FDA issued a warning letter to snushaven.com for selling misbranded nicotine pouches, specifically for selling to individuals under 21. The company is required to take prompt action to address violations of the Federal Food, Drug, and Cosmetic Act.

FDA Warning Letter to El Rey USA Meats & Seafood Inc.

The FDA issued a warning letter to El Rey USA Meats & Seafood Inc. on February 19, 2026, citing serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation. This follows a previous inspection and warning in January 2023, indicating a failure to implement required verification procedures for imported fish and fishery products.

FDA Warning Letter to idripejuice.com for Tobacco Products

The FDA issued a warning letter to idripejuice.com for selling electronic nicotine delivery system (ENDS) products to individuals under 21. The company's products were found to be misbranded due to these sales, violating the Federal Food, Drug, and Cosmetic Act.